ADAR1 Capital Management reports $56,041 InMed Pharmaceuticals share purchase
INM•ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals, reported additional common-share purchases totaling $56,041. Its holdings rose to 935,021 shares, with reported purchase prices of $1.3298 and $1.33 per share.
1. Reported purchases
ADAR1 Capital Management reported additional InMed Pharmaceuticals common-share purchases, bringing its holdings to 935,021 shares. The shares are held indirectly through private investment funds it manages; manager Daniel Schneeberger was listed as an indirect beneficial owner. Reported purchase prices were $1.3298 and $1.33 per share.
